Fair Value Measurements (Details) - USD ($)
$ in Thousands |
12 Months Ended |
|
Dec. 31, 2015 |
Dec. 31, 2014 |
Aug. 31, 2013 |
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Available-for-sale Securities |
|
$ 107
|
|
| Goodwill |
$ 0
|
15,545
|
|
| Fair Value, by Balance Sheet Grouping [Table Text Block] |
The valuation methodologies used for the Company's financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2015 |
|
Fair Value Measurements |
|
Carrying |
|
Fair |
|
As of December 31, 2015 |
|
Amount |
|
Value |
|
Level 1 |
|
Level 2 |
|
Level 3 |
Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents: |
|
|
|
|
|
|
|
|
|
Cash |
$ |
7,534 |
|
|
$ |
7,534 |
|
|
$ |
7,534 |
|
|
$ |
— |
|
|
$ |
— |
|
Money market funds |
776 |
|
|
776 |
|
|
776 |
|
|
— |
|
|
— |
|
|
$ |
8,310 |
|
|
$ |
8,310 |
|
|
$ |
8,310 |
|
|
$ |
— |
|
|
$ |
— |
|
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
$ |
48 |
|
|
$ |
48 |
|
|
$ |
48 |
|
|
$ |
— |
|
|
$ |
— |
|
Mutual funds |
58 |
|
|
58 |
|
|
58 |
|
|
— |
|
|
— |
|
U.S. Treasury securities |
1,115 |
|
|
1,115 |
|
|
1,115 |
|
|
— |
|
|
— |
|
Government agency securities |
131 |
|
|
131 |
|
|
131 |
|
|
— |
|
|
— |
|
|
$ |
1,352 |
|
|
$ |
1,352 |
|
|
$ |
1,352 |
|
|
$ |
— |
|
|
$ |
— |
|
Liabilities: |
|
|
|
|
|
|
|
|
|
Contingent consideration: |
|
|
|
|
|
|
|
|
|
Asuragen |
$ |
4,628 |
|
|
$ |
4,628 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
4,628 |
|
RedPath |
13,921 |
|
|
13,921 |
|
|
— |
|
|
— |
|
|
13,921 |
|
|
$ |
18,549 |
|
|
$ |
18,549 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
18,549 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2014 |
|
Fair Value Measurements |
|
Carrying |
|
Fair |
|
As of December 31, 2014 |
|
Amount |
|
Value |
|
Level 1 |
|
Level 2 |
|
Level 3 |
Assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents: |
|
|
|
|
|
|
|
|
|
Cash |
$ |
6,836 |
|
|
$ |
6,836 |
|
|
$ |
6,836 |
|
|
$ |
— |
|
|
$ |
— |
|
Money market funds |
16,275 |
|
|
16,275 |
|
|
16,275 |
|
|
— |
|
|
— |
|
|
$ |
23,111 |
|
|
$ |
23,111 |
|
|
$ |
23,111 |
|
|
$ |
— |
|
|
$ |
— |
|
Marketable securities: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
$ |
48 |
|
|
$ |
48 |
|
|
$ |
48 |
|
|
$ |
— |
|
|
$ |
— |
|
Mutual funds |
59 |
|
|
59 |
|
|
59 |
|
|
— |
|
|
— |
|
U.S. Treasury securities |
1,070 |
|
|
1,070 |
|
|
1,070 |
|
|
— |
|
|
— |
|
Government agency securities |
317 |
|
|
317 |
|
|
317 |
|
|
— |
|
|
— |
|
|
$ |
1,494 |
|
|
$ |
1,494 |
|
|
$ |
1,494 |
|
|
$ |
— |
|
|
$ |
— |
|
Liabilities: |
|
|
|
|
|
|
|
|
|
Contingent consideration: |
|
|
|
|
|
|
|
|
|
Asuragen |
$ |
4,476 |
|
|
$ |
4,476 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
4,476 |
|
RedPath |
22,066 |
|
|
22,066 |
|
|
— |
|
|
— |
|
|
22,066 |
|
|
$ |
26,542 |
|
|
$ |
26,542 |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
26,542 |
|
|
|
|
| Contingent consideration - deferred payments |
$ 18,549
|
26,542
|
$ 500
|
| Change in fair value of contingent consideration |
7,993
|
0
|
|
| Fair Value, Inputs, Level 3 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
18,549
|
26,542
|
|
| Goodwill, Fair Value Disclosure |
0
|
15,545
|
|
| Fair Value, Inputs, Level 1 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
8,310
|
23,111
|
|
| Investments, Fair Value Disclosure |
1,352
|
1,494
|
|
| Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
48
|
48
|
|
| Mutual Funds [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
58
|
59
|
|
| US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
1,115
|
1,070
|
|
| Government agency securities [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
131
|
317
|
|
| Cash [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
7,534
|
6,836
|
|
| Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
776
|
16,275
|
|
| Asuragen [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
4,628
|
4,476
|
|
| Change in fair value of contingent consideration |
(152)
|
|
|
| Asuragen [Member] | Fair Value, Inputs, Level 3 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
4,628
|
4,476
|
|
| RedPath |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
13,921
|
22,066
|
|
| Change in fair value of contingent consideration |
8,145
|
|
|
| RedPath | Fair Value, Inputs, Level 3 [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
13,921
|
22,066
|
|
| Reported Value Measurement [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
8,310
|
23,111
|
|
| Investments, Fair Value Disclosure |
1,352
|
1,494
|
|
| Contingent consideration - deferred payments |
18,549
|
26,542
|
|
| Reported Value Measurement [Member] | Money Market Funds [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
48
|
48
|
|
| Reported Value Measurement [Member] | Mutual Funds [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
58
|
59
|
|
| Reported Value Measurement [Member] | US Treasury Securities [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
1,115
|
1,070
|
|
| Reported Value Measurement [Member] | Government agency securities [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
131
|
317
|
|
| Reported Value Measurement [Member] | Cash [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
7,534
|
6,836
|
|
| Reported Value Measurement [Member] | Money Market Funds [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
776
|
16,275
|
|
| Reported Value Measurement [Member] | Asuragen [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
4,628
|
4,476
|
|
| Reported Value Measurement [Member] | RedPath |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
13,921
|
22,066
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
8,310
|
23,111
|
|
| Investments, Fair Value Disclosure |
1,352
|
1,494
|
|
| Contingent consideration - deferred payments |
18,549
|
26,542
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] | Money Market Funds [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
48
|
48
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] | Mutual Funds [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
58
|
59
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] | US Treasury Securities [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
1,115
|
1,070
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] | Government agency securities [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Investments, Fair Value Disclosure |
131
|
317
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] | Cash [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
7,534
|
6,836
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] | Money Market Funds [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Cash and Cash Equivalents, Fair Value Disclosure |
776
|
16,275
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] | Asuragen [Member] |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
4,628
|
4,476
|
|
| Estimate of Fair Value, Fair Value Disclosure [Member] | RedPath |
|
|
|
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] |
|
|
|
| Contingent consideration - deferred payments |
$ 13,921
|
$ 22,066
|
|